Specificity of adenosine deaminase inhibitors☆
References (35)
- et al.
Biochem. Pharmac.
(1975) - et al.
Biochem. Pharmac.
(1975) - et al.
J. biol. Chem.
(1973) - et al.
J. biol. Chem
(1975) - et al.
Biochem. Pharmac.
(1976) - et al.
Biochim. biophys. Acta
(1973) - et al.
Biochem. Pharmac.
(1974) - et al.
Biochim. biophys. Acta
(1976) - et al.
Clin. Biochem.
(1974) - et al.
J. Antibiot.
(1967)
J. Am. chem. Soc.
J. Heterocy. Chem.
J. med. Chem.
Can. J. Biochem.
Cancer Res.
Can. J. Biochem.
J. infect. Dis.
Cited by (110)
Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization
2019, Analytical BiochemistryCitation Excerpt :The development of a quantitative and selective method to determine the concentration of adenosine in tumors is needed to assess the impact that adenosine concentrations have on adenosine receptor targeted therapies, to understand differences in adenosine concentrations across different tumor models, and their relationship to response to adenosine antagonists. The method needs to overcome challenges in the quantitative bioanalysis of adenosine in biological matrices which includes: analyte hydrophilicity, low molecular weight, separation from other nucleosides, and a very short half-life from enzymatic degradation [3,5–9]. Additionally, the complexity of a tissue matrix poses problems regarding isolation of the compound of interest from matrix components that lead to perturbations in ionization efficiency in the mass spectrometer (MS).
Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938
2006, European Journal of PharmacologyAdenine nucleotide synthesis in human erythrocytes depends on the mode of supplementation of cell suspension with adenosine
1999, Blood Cells, Molecules, and DiseasesProcessing of adenosine receptor agonists in rat and human whole blood
1998, Biochemical Pharmacology
- ☆
This work was supported by the National Cancer Institute and Medical Research Council of Canada.